Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. (ADIL) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
adil · stock forecast · 3 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$8.00
Consensus
$8.00
+262.0% upside
Low
$8.00
Median: $8 · Last Close: $2.21
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.32 | ↑ 5.00% |
1-day model range: $2.29–$2.35. Peak: $2.35 (+5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ADIL · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-09-30 | Maxim Group | Upgrade ↑ | Hold→Buy |
| 2023-07-11 | Brookline Capital | Maintains | Buy→Buy |
| 2022-08-17 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2021-10-13 | Brookline Capital | Maintains | Buy→Buy |
| 2021-06-29 | Litchfield Hills | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Adial Pharmaceuticals, Inc. (ADIL) stock. Of the recent 5 rating actions, 1 were upgrades and 1 were downgrades. 3 analysts currently cover ADIL.
Analyst Recommendation Trends
ADIL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$46M
↓ 2.1% YoY
Revenue Next Year
$4M
↓ 90.4% YoY
EPS This Year
$-5.26
EPS Next Year
$-2.49
↓ 52.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast ADIL EPS of $-5.26 for the current fiscal year, based on estimates from 1 analysts. The ADIL revenue forecast is $46M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ADIL stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ADIL price target is $8.00 (+262.0% upside), with an analyst consensus of Buy.
The ADIL short-term stock prediction for tomorrow is $2.32 (+5.00%).
Adial Pharmaceuticals, Inc. trades on NASDAQ under the ticker ADIL. The ADIL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
ADIL forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month ADIL price target is $8.00, with a high forecast of $8.00 and a low of $8.00. The median price target is shown in the chart above when available. This implies +262.0% potential upside from the current price of $2.21.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.